Special Issue

Personalized Prediction Model-Based Treatment Decisions in Cancer Patients

Message from the Guest Editor

Cancer is a very heterogeneous disease, where patients, depending on their characteristics, can respond differently to treatment, thereby complicating clinical decision making. Clinical prediction models that combine patient, disease, and even treatment characteristics may facilitate personalized decision making.Aim and scope: This Special Issue will focus on research on the use of clinical prediction models to facilitate personalized treatment decisions in cancer patients.Personalized prediction model-based treatment decisions is a research field that operates at the intersection of prediction modelling and causal inference. More research is needed on how we can estimate, assess, and value potential treatment effects on the level of the individual patient using these (causal?) prediction models.We are looking for applied examples of and methodological research on the use of clinical prediction models to facilitate personalized treatment decisions in cancer patients.

Guest Editor

Dr. Ewoud Schuit

Julius Center for Health Sciences and Primary Care, Utrecht University Medical Center, Utrecht University, 3584 CG Utrecht, The Netherlands

Deadline for manuscript submissions

20 July 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).